Sareum Holdings (SAR) Price & Analysis

Compare

26 Followers

SAR Stock Chart & Stats

15.00p

0.10p(0.44%)

At close: Jan 09 4:00 PM EST

15.00p

0.10p(0.44%)

Day’s Range― - ―

52-Week Range9.50p - 29.00p

Previous CloseN/A

Volume41.80K

Average Volume (3M)619.72K

Market Cap

£21.40M

Enterprise Value16.89M

Total Cash (Recent Filing)£3.55M

Total Debt (Recent Filing)£0.00

Price to Earnings (P/E)―

Beta-0.66

Next Earnings

Mar 26, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.02

Shares Outstanding138,065,170

10 Day Avg. Volume1,134,615

30 Day Avg. Volume619,716

Financial Highlights & Ratios

PEG Ratio0.31

Price to Book (P/B)8.68

Price to Sales (P/S)0.00

P/FCF Ratio-7.75

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)-0.02

Revenue Forecast (FY)£43.15M

Bulls Say, Bears Say

Bulls Say

No Reported DebtA debt-free balance sheet materially lowers fixed financing costs and reduces bankruptcy risk, giving management structural flexibility to time R&D spending, pursue licensing discussions or small acquisitions without near-term interest obligations, aiding multi-quarter strategic planning.

Asset Monetisation Business ModelA licensing-and-partnership model is durable for a discovery-stage biotech: it converts R&D into milestone and royalty streams without the need to commercialise products directly. This supports scalability and limits fixed commercial costs if the pipeline yields partnerable candidates.

Specialised Kinase PlatformFocus on a specific small-molecule kinase platform creates repeatable scientific expertise and IP that can spawn multiple programs and partnership opportunities. Platform depth improves hit-to-lead efficiency and enhances long-term out-licensing potential across therapeutic areas.

Bears Say

Pre-revenue With Widening LossesAbsence of product revenue and widening net losses erode equity cushions and limit internal funding options. Over multiple quarters this makes the business more reliant on externals for survival and increases execution risk if milestone timelines slip or deals delay.

Persistent Cash BurnSustained negative operating and free cash flow means the company cannot self-fund development. This structural cash deficit forces serial fundraising or partner dependence, raising dilution risk and putting pressure on program continuity if external capital slows.

Small, Volatile Equity BaseA limited and fluctuating equity base reduces the firm’s capacity to weather R&D setbacks and increases sensitivity to capital markets. Reliance on episodic funding rounds can disrupt long-term planning and bargaining power in partner negotiations.

Sareum Holdings News

Sareum Restarts Phase 2-Enabling Toxicology Programme for Lead Autoimmune Drug SDC-1801

Sareum Holdings ( ($GB:SAR) ) has shared an announcement. Sareum Holdings has restarted its Phase 2-enabling toxicology programme...

11d ago

Sareum Holdings Passes All Resolutions at AGM, Strengthening Governance

Sareum Holdings ( ($GB:SAR) ) has shared an announcement. Sareum Holdings plc announced that all resolutions at its...

3M ago

Sareum Holdings Advances Pipeline and Strengthens Portfolio

Sareum Holdings ( ($GB:SAR) ) has shared an update. Sareum Holdings has made significant progress in its pipeline,...

3M ago

Sareum Holdings Announces AGM and Releases Annual Report

Sareum Holdings ( ($GB:SAR) ) has provided an update. Sareum Holdings PLC has announced its Annual General Meeting...

3M ago

Sareum Holdings Enhances Financial Advisory Team with New Joint Broker Appointment

The latest announcement is out from Sareum Holdings ( ($GB:SAR) ). Sareum Holdings PLC has appointed Singer Capital...

4M ago

Sareum Holdings Reports Progress in Drug Development and Strategic Collaborations

Sareum Holdings ( ($GB:SAR) ) has issued an announcement. Sareum Holdings PLC announced its unaudited financial results for...

4M ago

Sareum Holdings Discontinues Toxicology Study for SDC-1801 Amid Safety Concerns

Sareum Holdings ( ($GB:SAR) ) has issued an announcement. Sareum Holdings has discontinued its 16-week GLP preclinical toxicology...

5M ago

Sareum Holdings to Announce Financial Results and Host Investor Presentation

Sareum Holdings ( ($GB:SAR) ) has issued an announcement. Sareum Holdings PLC announced it will release its financial...

5M ago

Sareum Holdings Raises Funds Through Warrant Exercise

Sareum Holdings ( ($GB:SAR) ) just unveiled an announcement. Sareum Holdings announced the exercise of warrants for 20,200...

5M ago

Sareum Holdings Increases Share Capital Through Warrant Exercise

Sareum Holdings ( ($GB:SAR) ) just unveiled an announcement. Sareum Holdings plc announced the exercise of warrants to...

5M ago

SAR FAQ

What was Sareum Holdings PLC’s price range in the past 12 months?

Sareum Holdings PLC lowest share price was 9.50p and its highest was 29.00p in the past 12 months.

What is Sareum Holdings PLC’s market cap?

Sareum Holdings PLC’s market cap is £21.40M.

When is Sareum Holdings PLC’s upcoming earnings report date?

Sareum Holdings PLC’s upcoming earnings report date is Mar 26, 2026 which is in 26 days.

How were Sareum Holdings PLC’s earnings last quarter?

Sareum Holdings PLC released its earnings results on Oct 23, 2025. The company reported -0.024p earnings per share for the quarter, missing the consensus estimate of N/A by -0.024p.

Is Sareum Holdings PLC overvalued?

According to Wall Street analysts Sareum Holdings PLC’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Sareum Holdings PLC pay dividends?

Sareum Holdings PLC does not currently pay dividends.

What is Sareum Holdings PLC’s EPS estimate?

Sareum Holdings PLC’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Sareum Holdings PLC have?

Sareum Holdings PLC has 138,065,170 shares outstanding.

What happened to Sareum Holdings PLC’s price movement after its last earnings report?

Sareum Holdings PLC reported an EPS of -0.024p in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 17.857%.

Which hedge fund is a major shareholder of Sareum Holdings PLC?

Currently, no hedge funds are holding shares in GB:SAR

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Sareum Holdings PLC

Sareum Holdings plc, a specialist drug development company, engages in the discovery and development of therapeutic drugs for cancer and autoimmune diseases. It develops small molecule therapeutic drugs based on its Sareum Kinase Inhibitor Library drug discovery platform. The company's product pipeline includes Checkpoint Kinase 1, Aurora+FLT3 kinase, and TYK2/JAK1 kinase. It has collaborations with Hebei Medical University Biomedical Engineering Center and Sierra Oncology, Inc. The company was founded in 2003 and is based in Cambridge, the United Kingdom.